leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharma says University of Texas study identifies Ifenprodil as one of several possible drug candidate to treat coronavirus

The study identified interactions between the immune system and nerves in the lungs that can cause a rapid deterioration in patients 

covid
Algernon plans to launch a multinational Phase 2b/3 human trial of Ifenprodil as a potential therapeutic treatment for COVID-19 sufferers

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) said Tuesday an independent research study by the University of Texas at Dallas has identified Ifenprodil as one of several possible drug candidates to treat the coronavirus (COVID-19) disease. 

The company’s announcement of the study comes as it plans to launch a multinational Phase 2b/3 human trial of Ifenprodil as a potential therapeutic treatment for COVID-19 sufferers. 

“This study provides significant additional data to what we have already identified, suggesting that Ifenprodil may be an effective treatment for COVID-19,” Algernon CEO Christopher Moreau said in a statement.

READ: Algernon unveils first US clinical trial site in Florida for Phase 2b/3 human study of Ifenprodil as potential coronavirus treatment

Vancouver-based Algernon said the study, recently published online in 'Brain, Behaviour and Immunity', identified interactions between the immune system and nerves in the lungs that can cause a rapid deterioration in COVID-19 patients. 

The authors looked at the relative gene abundance in the lungs of COVID-19 patients compared to the lungs of healthy controls. In addition to genes that might be expected to be upregulated, the levels of the gene that expressed the NMDA GluN2B receptor in immune cells were also greatly increased.

The company noted that the researchers suggested that interrupting the interaction between the NMDA receptor and glutamate, one of the neurotransmitters that NMDA receptors respond to, could lessen the damage caused by the infection.

Ifenprodil is an NMDA receptor antagonist specifically targeting the GluN2B subunit, preventing glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.

Algernon said it believes that Ifenprodil may reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.

“We were really taken aback at the upregulation of NMDA receptors in severe COVID-19 patients,” said Dr Theodore Price, one of the co-authors of the study. 

“We were even more surprised when we noted that it was an immune-based signal and not neuronal. Based on our findings, we think there is significant opportunity in disrupting NMDA receptor signalling in the lung for reversing pathology in COVID.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.275 CAD

CSE:AGN
Market: CSE
Market Cap: $30.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll...

Algernon Pharmaceutical (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has now enrolled a third of their patients in the Phase 2B/3 study of their repurposed drug Ifenprodil. Moreau discusses hitting that mark and also...

on 09/02/2020

2 min read